echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The next-generation PDE4 inhibitor introduced by Cinda exceeds 200 million US dollars to apply for clinical application in China

    The next-generation PDE4 inhibitor introduced by Cinda exceeds 200 million US dollars to apply for clinical application in China

    • Last Update: 2022-05-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Cube Info

    Author: info

    On May 5, the CDE official website showed that the clinical application for Orismilast sustained-release tablets jointly developed by Innovent Bio and UNION therapeutics was accepted by the State Food and Drug Administration


    orismilast is a potent and highly selective next-generation PDE4 inhibitor with broad anti-inflammatory properties


    In September 2021, Cinda and UNION reached an exclusive right to research, develop and commercialize orismilast in China (including mainland China, Hong Kong, Macau and Taiwan)


    There are about 50 million patients with atopic dermatitis and 6 million patients with psoriasis in China, and the incidence shows a gradual upward trend with life>


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.